Bio Essence Corp (BIOE) stock
BIOEOTCPharmaceutical PreparationsFiscal year ends December 31
$0.42+0.03 (+7.72%)
Close on Oct 19, 2026Market cap $22.70MP/E 10.5Yield –
Bio Essence operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Bio Essence's operating income for the twelve months ending Sep 30, 2026 was $1.37M. For fiscal 2025 it was $900.01K. The highest annual figure on record is $900.01K in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $900.01K | – |
| FY2024 | Dec 31, 2024 | -$459.44K | – |
| FY2023 | Dec 31, 2023 | -$345.59K | – |
| FY2022 | Dec 31, 2022 | -$511.14K | – |
| FY2021 | Dec 31, 2021 | -$857.53K | – |
| FY2020 | Dec 31, 2020 | -$832.57K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$159.13K | -1216.4% |
| Q2 FY2026 | Jun 30, 2026 | $279.29K | +356.2% |
| Q1 FY2026 | Mar 31, 2026 | $215.80K | – |
| Q4 FY2025 | Dec 31, 2025 | $1.03M | +26629.7% |
| Q3 FY2025 | Sep 30, 2025 | $14.25K | – |
| Q2 FY2025 | Jun 30, 2025 | $61.22K | – |
| Q1 FY2025 | Mar 31, 2025 | -$205.09K | – |
| Q4 FY2024 | Dec 31, 2024 | $3.85K | – |
| Q3 FY2024 | Sep 30, 2024 | -$146.45K | – |
| Q2 FY2024 | Jun 30, 2024 | -$165.01K | – |
| Q1 FY2024 | Mar 31, 2024 | -$151.83K | – |
| Q4 FY2023 | Dec 31, 2023 | -$195.48K | -406.6% |
| Q3 FY2023 | Sep 30, 2023 | -$82.64K | – |
| Q2 FY2023 | Jun 30, 2023 | -$43.16K | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.31K | – |
| Q4 FY2022 | Dec 31, 2022 | $63.76K | – |
| Q3 FY2022 | Sep 30, 2022 | -$192.57K | – |
| Q2 FY2022 | Jun 30, 2022 | -$155.90K | – |
| Q1 FY2022 | Mar 31, 2022 | -$226.43K | – |
| Q4 FY2021 | Dec 31, 2021 | -$198.77K | – |
| Q3 FY2021 | Sep 30, 2021 | -$192.93K | – |
| Q2 FY2021 | Jun 30, 2021 | -$261.30K | – |
| Q1 FY2021 | Mar 31, 2021 | -$204.53K | – |
| Q4 FY2020 | Dec 31, 2020 | -$328.82K | – |
| Q3 FY2020 | Sep 30, 2020 | -$187.14K | – |
| Q2 FY2020 | Jun 30, 2020 | -$196.26K | – |
| Q1 FY2020 | Mar 31, 2020 | -$120.34K | – |
See a number that looks wrong?